HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Akiyoshi Ohtake Selected Research

G 1617

1/2007Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Akiyoshi Ohtake Research Topics

Disease

9Overactive Urinary Bladder (Overactive Bladder)
11/2013 - 05/2004
7Urinary Bladder Neck Obstruction (Bladder Neck Obstruction)
07/2022 - 03/2006
4Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
06/2019 - 02/2008
3Lower Urinary Tract Symptoms
01/2018 - 08/2004
3Cerebral Infarction
03/2013 - 02/2007
2Urologic Diseases (Urinary Tract Disease)
06/2019 - 03/2019
2Melanoma (Melanoma, Malignant)
11/2004 - 09/2004
1Body Weight (Weight, Body)
08/2021
1Hyperphagia (Overeating)
08/2021
1Weight Gain
08/2021
1Hyperplasia
01/2018
1Ischemia
11/2010
1Reperfusion Injury
11/2010
1Nocturia
04/2010
1Cognitive Dysfunction
02/2007
1Infarction (Infarctions)
02/2007
1Urge Urinary Incontinence (Urge Incontinence)
01/2007
1Miosis
02/2006
1Mydriasis
02/2006
1Urinary Retention
04/2005
1Dysuria
08/2004

Drug/Important Bio-Agent (IBA)

8Solifenacin SuccinateFDA Link
01/2010 - 05/2004
6Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA
07/2022 - 05/2004
6Tamsulosin (Flomax)FDA LinkGeneric
11/2010 - 08/2004
4Muscarinic AntagonistsIBA
01/2010 - 05/2004
4Endothelins (Endothelin)IBA
02/2008 - 09/2004
3mirabegronIBA
11/2013 - 01/2013
3N- (6- methoxy- 5- (2- methoxyphenoxy)- 2- (pyrimidin- 2- yl)pyrimidin- 4- yl)- 2- phenylethenesulfonamide (YM598)IBA
02/2008 - 09/2004
2Adrenergic Receptors (Adrenergic Receptor)IBA
07/2022 - 02/2008
2AtropineFDA LinkGeneric
07/2022 - 05/2004
2ASP6432IBA
06/2019 - 03/2019
2darifenacinFDA Link
02/2007 - 05/2004
2Tolterodine Tartrate (Detrol)FDA Link
02/2007 - 05/2004
2AtrasentanIBA
11/2004 - 09/2004
2Bosentan (Tracleer)FDA Link
11/2004 - 09/2004
1Midodrine (Midon)FDA LinkGeneric
07/2022
1fezolinetantIBA
08/2021
1Estradiol (Delestrogen)FDA LinkGeneric
08/2021
1Follicle Stimulating Hormone (Follitropin)FDA Link
08/2021
1Luteinizing Hormone (Lutropin)FDA LinkGeneric
08/2021
1GABA-A Receptor AgonistsIBA
04/2010
1gamma-Aminobutyric Acid (GABA)IBA
04/2010
1Zolpidem (Ambien)FDA LinkGeneric
04/2010
1Cholinergic Antagonists (Anticholinergics)IBA
02/2007
1salicylhydroxamic acid (SHAM)IBA
02/2007
1Scopolamine (Hyoscine)FDA Link
02/2007
1G 1617IBA
01/2007
1Endothelin-1 (Endothelin 1)IBA
06/2006
1Phenylephrine (Neo-Synephrine)FDA LinkGeneric
02/2006
1Prazosin (Minipress)FDA LinkGeneric
02/2006
1naftopidilIBA
02/2006
1alfuzosin (UroXatral)FDA Link
02/2006
1Doxazosin (Cardura)FDA LinkGeneric
02/2006
1Terazosin (Hytrin)FDA LinkGeneric
02/2006
1Pharmaceutical PreparationsIBA
04/2005
1Endothelin Receptor AntagonistsIBA
09/2004
1SaltsIBA
09/2004
1oxybutynin (Tavor)FDA LinkGeneric
05/2004

Therapy/Procedure

2Drug Therapy (Chemotherapy)
06/2019 - 01/2018
1Therapeutics
06/2019
1Ligation
09/2006
1Injections
02/2006